GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Guardion Health Sciences Inc (NAS:GHSI) » Definitions » Beneish M-Score

Guardion Health Sciences (Guardion Health Sciences) Beneish M-Score : 0.00 (As of Jun. 07, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Guardion Health Sciences Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Guardion Health Sciences's Beneish M-Score or its related term are showing as below:

During the past 9 years, the highest Beneish M-Score of Guardion Health Sciences was 107.63. The lowest was -14.07. And the median was -2.66.


Guardion Health Sciences Beneish M-Score Historical Data

The historical data trend for Guardion Health Sciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardion Health Sciences Beneish M-Score Chart

Guardion Health Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only -2.32 -14.07 60.09 -3.26 -

Guardion Health Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.93 -3.57 -2.98 - -

Competitive Comparison of Guardion Health Sciences's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Guardion Health Sciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guardion Health Sciences's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Guardion Health Sciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Guardion Health Sciences's Beneish M-Score falls into.



Guardion Health Sciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Guardion Health Sciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $2.10 Mil.
Revenue was 3 + 2.936 + 3.337 + 2.79 = $12.06 Mil.
Gross Profit was 1.179 + 1.35 + 1.46 + 1.249 = $5.24 Mil.
Total Current Assets was $10.38 Mil.
Total Assets was $10.41 Mil.
Property, Plant and Equipment(Net PPE) was $0.03 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.02 Mil.
Selling, General, & Admin. Expense(SGA) was $8.65 Mil.
Total Current Liabilities was $1.27 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was -4.747 + 0.425 + 0.373 + -1.172 = $-5.12 Mil.
Non Operating Income was -3.802 + 1.027 + 1.051 + -0.255 = $-1.98 Mil.
Cash Flow from Operations was -0.755 + -1.318 + -0.767 + -0.407 = $-3.25 Mil.
Total Receivables was $1.95 Mil.
Revenue was 3.186 + 2.726 + 2.664 + 3.275 = $11.85 Mil.
Gross Profit was 1.335 + 0.936 + 1.088 + 1.4 = $4.76 Mil.
Total Current Assets was $14.37 Mil.
Total Assets was $14.42 Mil.
Property, Plant and Equipment(Net PPE) was $0.05 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.94 Mil.
Selling, General, & Admin. Expense(SGA) was $10.61 Mil.
Total Current Liabilities was $2.18 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2.103 / 12.063) / (1.947 / 11.851)
=0.174335 / 0.16429
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(4.759 / 11.851) / (5.238 / 12.063)
=0.401569 / 0.43422
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (10.382 + 0.025) / 10.407) / (1 - (14.373 + 0.046) / 14.419)
=0 / 0
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=12.063 / 11.851
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.936 / (0.936 + 0.046)) / (0.02 / (0.02 + 0.025))
=0.953157 / 0.444444
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(8.646 / 12.063) / (10.611 / 11.851)
=0.716737 / 0.895367
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 1.271) / 10.407) / ((0 + 2.178) / 14.419)
=0.122129 / 0.151051
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-5.121 - -1.979 - -3.247) / 10.407
=0.010089

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.


Guardion Health Sciences Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Guardion Health Sciences's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Guardion Health Sciences (Guardion Health Sciences) Business Description

Traded in Other Exchanges
Address
2925 Richmond Avenue, Suite 1200, Houston, TX, USA, 77098
Guardion Health Sciences Inc is a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product. The company's Medical Foods include Lumega-Z and GlaucoCetin; Medical Devices include Mapcat SF, VectorVision, CSV-1000 and CSV-2000; Nutraceuticals include ImmuneSF.
Executives
Katharine Joan Cox officer: Chief Accounting Officer 2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Janet Hall officer: CEO & President 2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Bradley Louis Radoff 10 percent owner 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
Family Foundation Radoff other: See Footnote 1 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
Michaela Griggs director 2925 RICHMOND AVENUE, SUITE 1200, HOUSTON TX 77098
Bret Scholtes director, officer: Chief Executive Officer 2105 CITY WEST BLVD., SUITE 500, HOUSTON TX 77042
Donald A Gagliano director 131 CARDINAL AVE, SAN ANTONIO TX 78209
Jeffrey S Benjamin officer: Chief Accounting Officer 3885 CRESTWOOD PARKWAY, SUITE 550, DULUTH GA 30096
Craig Sheehan officer: Chief Commercial Officer 15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Andrew C Schmidt officer: Chief Financial Officer 1700 CARNEGIE AVE, SUITE 100, SANTA ANA CA 92705
Kelly Anderson director C/O TOMI ENVIRONMENTAL SOLUTIONS, INC., 9454 WILSHIRE BLVD., R-1, BEVERLY HILLS CA 90212
David W Evans director, officer: Chief Scientific Officer 4141 JUTLAND DRIVE, SUITE 215, SAN DIEGO CA 92117
Tamara A Evans 10 percent owner 4141 JUTLAND DRIVE, SUITE 215, SAN DIEGO CA 92117
Vincent J Roth officer: General Counsel and Secretary 15150 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Robert N Weingarten director 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367

Guardion Health Sciences (Guardion Health Sciences) Headlines